Effects of progestational agents in treatment of endometrial carcinoma.
Progestational agents induced an objective response in 11.2% of 155 patients with advanced primary or recurrent endometrial carcinoma. Response rates decreased with decreasing tumor differentiation from 40% with Broders grade 1 lesions to 17.5, 2.4, and 0%, respectively, with grades 2, 3, and 4. 17 alpha-Hydroxyprogesterone caproate (Delalutin), 6,17 alpha-dimethyl-6-dehydroprogesterone (Colprone), and 6-methyl-6-dehydroprogesterone acetate (Megace) were the progestogens used; there was no significant advantage for any one agent. Overall, survival after initiation of hormone therapy was 40% at one year, 19% at two years, and 8% at five years. Survival was highly dependent on the degree of tissue differentiation (P less than .001) and was influenced significantly by the estimated tumor volume at the start of therapy (P less than .01) and by the time interval from primary treatment to the beginning of hormone therapy (P less than .01).
D000077713:17 alpha-Hydroxyprogesterone Caproate; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use; D008524:Medrogestone / Q000627:therapeutic use; D008535:Megestrol / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D045167:Progesterone Congeners / Q000627:therapeutic use*; D011379:Prognosis; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D006908:Hydroxyprogesterones; D045167:Progesterone Congeners; D008524:Medrogestone; D000077713:17 alpha-Hydroxyprogesterone Caproate; D008535:Megestrol